Hormones and cardiovascular disease, what the Danish Nurse Cohort learned us



Similar documents
Randomized trials versus observational studies

EXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA

Quantifying Life expectancy in people with Type 2 diabetes

Malmö Preventive Project. Cardiovascular Endpoints

The Women s Health Initiative: The Role of Hormonal Therapy in Disease Prevention

Malmö Preventive Project. Cardiovascular Endpoints

Cardiovascular Endpoints

Cardiovascular Endpoints

FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES

Statins and Risk for Diabetes Mellitus. Background

Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study

The Women s Health Initiative where are we a decade later?

With Big Data Comes Big Responsibility

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial

Research Skills for Non-Researchers: Using Electronic Health Data and Other Existing Data Resources

Psoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis

Guide to Biostatistics


Tips for surviving the analysis of survival data. Philip Twumasi-Ankrah, PhD

Prognostic impact of uric acid in patients with stable coronary artery disease

Mortality Assessment Technology: A New Tool for Life Insurance Underwriting

Hormone therapy and breast cancer: conflicting evidence. Cindy Farquhar Cochrane Menstrual Disorders and Subfertility Group

The WHI 12 Years Later: What Have We Learned about Postmenopausal HRT?

Main Effect of Screening for Coronary Artery Disease Using CT

The Diagnosis of Gap Between PrescriptionRegries

Cohort Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University

Impact of Massachusetts Health Care Reform on Racial, Ethnic and Socioeconomic Disparities in Cardiovascular Care

Incorrect Analyses of Radiation and Mesothelioma in the U.S. Transuranium and Uranium Registries Joey Zhou, Ph.D.

Appendix: Description of the DIETRON model

Big data size isn t enough! Irene Petersen, PhD Primary Care & Population Health

SUPPLEMENTARY MATERIALS. Rivaroxaban for Stroke Prevention in East Asian Patients from the ROCKET AF Trial

Diabetes Complications

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group

Bios 6648: Design & conduct of clinical research

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

An Application of the G-formula to Asbestos and Lung Cancer. Stephen R. Cole. Epidemiology, UNC Chapel Hill. Slides:

Stage 1 Meaningful Use for Specialists. NYC REACH Primary Care Information Project NYC Department of Health & Mental Hygiene

Performance Measurement for the Medicare and Medicaid Eligible (MME) Population in Connecticut Survey Analysis

Η δίαιτα στην πρόληψη του αγγειακού εγκεφαλικού επεισοδίου

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI

General and Abdominal Adiposity and Risk of Death in Europe

Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety

Design and principal results

Atrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

Coronary Heart Disease (CHD) Brief

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

NHS Diabetes Prevention Programme (NHS DPP) Non-diabetic hyperglycaemia. Produced by: National Cardiovascular Intelligence Network (NCVIN)

Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires

The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery

Analysis of Population Cancer Risk Factors in National Information System SVOD

A Multi-locus Genetic Risk Score for Abdominal Aortic Aneurysm

Mediterranean diet: A heart-healthy eating plan Source: mayoclinic.org/mediterranean-diet

Le conferme dalla real life superano gli studi registrativi

Managing diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)

Diabetes Prevention in Latinos

Summary ID# Clinical Study Summary: Study F3Z-JE-PV06

An Introduction to Medication Adherence

Chapter 3: Review of Literature Stroke

Are Men Losing Their Gonads?

Selected Health Status Indicators DALLAS COUNTY. Jointly produced to assist those seeking to improve health care in rural Alabama

Basic Study Designs in Analytical Epidemiology For Observational Studies

Case Study 11: Hormone Replacement Therapy

Study Design and Statistical Analysis

What are confidence intervals and p-values?

Insulin Resistance and PCOS: A not uncommon reproductive disorder

Electronic health records to study population health: opportunities and challenges

HEALTH MANAGEMENT PLAN PROGRAMME

on behalf of the AUGMENT-HF Investigators

3/2/2010 Post CABG R h e bili a i tat on Ahmed Elkerdany Professor o f oof C ardiac Cardiac Surgery Ain Shams University 1

The importance of adherence and persistence: The advantages of once-daily dosing

Understanding Diseases and Treatments with Canadian Real-world Evidence

Neal Rouzier responds to the JAMA article on Men and Testosterone

Beyond Age and Sex: Enhancing Annuity Pricing

4/4/2013. Mike Rizo, Pharm D, MBA, ABAAHP THE PHARMACIST OF THE FUTURE? METABOLIC SYNDROME AN INTEGRATIVE APPROACH

Using Health Information Technology to Improve Quality of Care: Clinical Decision Support

Success factors in Behavioral Medicine

Kai-Lit Phua. Introduction

Transcription:

Hormones and cardiovascular disease, what the Danish Nurse Cohort learned us Ellen Løkkegaard, Clinical Associate Professor, Ph.d. Dept. Obstetrics and Gynecology. Hillerød Hospital, University of Copenhagen

Design: Longitudinal observational study 1993 The Danish Nurse Cohort Study Questionnaire 23,178 female Danish Nurses >44 years Respons n=19,898 (86%) Postmenopausal women n=13,084

Design: Longitudinal observational study 1993 Questionnaire 23,178 female Danish Nurses >44 years Respons n=19,898 (86%) Never Users 58% Postmenopausal women n=13,084 HRT Exposure 10% Unopposed Estrogen Past Users 14% Current Users 28% 18% Combined Estrogen+progestin

Design: Longitudinal observational study 1993 Questionnaire 23,178 female Danish Nurses >44 years Respons n=19,898 (86%) Postmenopausal women n=13,084 Covariates Smoking Alcohol/week Body mass Index (BMI) Physical activity Hypertension Heart medication Diabetes Metabolic disease Familiar predisposition Self-rated health

Design: Longitudinal observational study 1993 Questionnaire National Registers of Hospital Discharges and Death End of 1998 Registers 23,178 female Danish Nurses >44 years Respons n=19,898 (86%) Ischemic Heart Disease - of those MI Stroke n=351 n=108 n=144 Death n=971 Postmenopausal women n=13,084

Cox proportional harzard p h(t,x) = h0(t) exp[ Σ βi xi ] i=1 Event Censur End of follow-up 45 50 55 60 65 Age

Hazard ratios (95% confidence intervals) for risk of death, according to use of hormone replacement therapy at baseline BMJ VOLUME 326 22 FEBRUARY 2003 bmj.com

Hazard ratios (95% confidence intervals) for risk of ischemic heart disease and myocardial infarction according to use of hormone replacement therapy at baseline. BMJ VOLUME 326 22 FEBRUARY 2003 bmj.com

Differential effects Hormone exposition Cardiovascular disease Cardiovascular risk-factor, present Confounder Hormone exposition Cardiovascular disease Cardiovascular Confounder risk-factor, not present

Ischemic heart disease Kaplan - Meier estimater 1.00 0.75 No diabetes 0.50 Never HT Ever HT 0.25 Diabetes Never HT Ever HT 0.00 40 60 age 80 100 Løkkegaard, E et al. BMJ 2003;326:426

Risk of ischemic heart disease with Hormone Therapy stratified on presence of diabetes Løkkegaard, E et al. BMJ 2003;326:426 Copyright 2003 BMJ Publishing Group Ltd.

The Danish Nurse Cohorte vs. literature Cardiovascular disease Stroke Review (Nelson, 2002) The Danish Nurse Cohort The Women s health initiative, JAMA 2002

Danish Nurse Cohorte vs. literature Total follow-up due to national registerbased end-point definitions No healthy user bias in the Danish Nurse Cohort study No protective effect from hormone therapy on cardiovascular disease

DAnish HOrmone Register Study (DAHORS)

DAnish Hormone Register Study (DAHORS)

DAnish Hormone Register Study (DAHORS)

DAnish Hormone Register Study (DAHORS)

National register based observational study 1995 National prescription registry 698,098 healthy women Above 51 years 2,987,068 person years Eur Heart Journal (2008) 29, 2660-8 HT Exposure 18% 8% 74% Never Previous Current

National register based observational study Endpoints 1995 National prescription registry 698,098 healthy women Above 51 years 2,987,068 person years Eur Heart Journal (2008) 29, 2660-8 Ult. 2000 National Patient - and Cause of Death Registry 4947 incident cases of Myocardial infarctions (MI) (ICD I21-I22)

National register based observational study Covariates Age 51-54, 55-59, 60-64, 65-69 Calendar year 1995, 1996,.. 2000) Other medications for Hypertension Diabetes Hypercholesterolemia Antiarrhythmics Geographical region Region Education No occupational practice Occupational practice Academic education Unknown Eur Heart Journal (2008) 29, 2660-8

Risk of Myocardial Infarction for women aged 51-70 Never 0,0 1,0 2,0 1,00 Estrogen 0,94 WHI E 0,95 Continous comb. 1,35 WHI E+P 1,24 Eur Heart Journal (2008) 29, 2660-8

DAHORS versus Never 0,0 1,0 2,0 WHI 1,00 Estrogen 0,94 WHI E 0,95 Continous comb. 1,35 WHI E+P 1,24

Modification from concomitant intake of medication for diabetes No, previous 0,0 1,0 2,0 3,0 0,85 Diabetes, previous 1,07 No,current 1,10 P-value for interaction 0.51 Eur Heart Journal (2008) 29, 2660-8 Diabetes,current 1,01

Danish Nurse Cohorte vs. DaHoRS The interaction between use of hormone therapy and medication for diabetes and risk of cardiovascular disease found in the Danish Nurse Cohort Study was not retrieved. Mayby there is an unhealthy user bias in the Danish Nurse Cohort study implying nurses having severe diabetes use HT more often. No protective effect from hormone therapy on cardiovascular disease, rather increased risk with combined therapy.